# EDGAR Filing Document

**Accession Number:** 0001782594
**File Stem:** 0001104659-23-004442
**Filing Date:** 2023-1
**Character Count:** 6835
**Document Hash:** 73f847fc91ced1fb03e31379ca4fdd67
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-004442.hdr.sgml**: 20230118

**ACCESSION NUMBER**: 0001104659-23-004442

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20230118

**FILED AS OF DATE**: 20230118

**DATE AS OF CHANGE**: 20230118

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Genetron Holdings Ltd
- **CENTRAL INDEX KEY:** 0001782594
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MEDICAL LABORATORIES [8071]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39328
- **FILM NUMBER:** 23532902

**BUSINESS ADDRESS:**
- **STREET 1:** 1-2/F, BUILDING 11, ZONE 1
- **STREET 2:** NO.8 LIFE SCIENCE PARKWAY
- **CITY:** CHANGPING DISTRICT, BEIJING
- **STATE:** F4
- **ZIP:** 102206
- **BUSINESS PHONE:** 86 (10) 5090 7500

**MAIL ADDRESS:**
- **STREET 1:** 1-2/F, BUILDING 11, ZONE 1
- **STREET 2:** NO.8 LIFE SCIENCE PARKWAY
- **CITY:** CHANGPING DISTRICT, BEIJING
- **STATE:** F4
- **ZIP:** 102206

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the Month of January 2023**

**Commission File Number: 001-39328**

**Genetron Holdings Limited**

**(Exact Name of Registrant as Specified in Its Charter)**

**1-2/F, Building 11, Zone 1**

**No.8 Life Science Parkway**

**Changping District, Beijing, 102206**

**People's Republic of China**

**+86 10 5090-7500**

**(Address of principal executive offices)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ⌧ Form 40-F ◻

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ◻

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ◻

**EXHIBIT INDEX**

---

| | |
|:---|:---|
| **Exhibit** | **Description** |
| [99.1](tm233748d1_ex99-1.htm) | [Press Release titled "Genetron Health Regains Compliance with Nasdaq Minimum Price Requirement"](tm233748d1_ex99-1.htm) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
| **Genetron Holdings Limited** | **Genetron Holdings Limited** |
| By: | /s/ Sizhen Wang |
| Name: | Sizhen Wang |
| Title: | Chief Executive Officer |

---

Date: January 18, 2023

## Exhibit 99.1

**Exhibit 99.1**

**Genetron health REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT**

BEIJING, China, January 18, 2023 (GLOBE NEWSWIRE) -- Genetron Holdings Limited ("Genetron Health" or the "Company", NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that the Company had received a notification letter ("Compliance Notice") from the staff of the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq"), dated January 17, 2023, indicating that the Company has regained compliance with the minimum bid price requirement set forth under the Nasdaq Listing Rule 5450(a)(1) (the "Minimum Bid Price Requirement").

As previously announced, the Company was notified by Nasdaq on October 28, 2022 that the Company was not in compliance with the Minimum Bid Price Requirement as the bid price of the Company's American depositary shares ("ADSs") closed below US$1.00 per share for 30 consecutive business days.

On January 17, 2023, Nasdaq confirmed in the Compliance Notice that for the ten consecutive business days, from December 29, 2022 to January 13, 2023, the closing bid price of the Company's ADSs has been at US$1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5450(a)(1), and the matter is closed.

**About Genetron Holdings Limited**

Genetron Holdings Limited ("Genetron Health" or the "Company") (Nasdaq: GTH) is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The Company has developed a comprehensive oncology portfolio that covers the entire spectrum of cancer management, addressing needs and challenges from early screening, diagnosis and treatment recommendations, as well as continuous disease monitoring and care. Genetron Health also partners with global biopharmaceutical companies and offers customized services and products. For more information, please visit ir.genetronhealth.com.

**Safe Harbor Statement**

This press release contains forward-looking statements made under the "safe harbor" provisions of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Genetron Health may also make written or oral forward-looking statements in its periodic reports to the SEC, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Genetron Health's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: impact of the COVID-19 pandemic, Genetron Health's goal and strategies; its future business development, financial condition and results of operations; Genetron Health's expectations regarding demand for, and market acceptance of, its services; the laws and regulations relating to Genetron Health's industry; the general economic and business conditions; and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in Genetron Health's filings with the SEC. All information provided in this announcement and in the attachments is as of the date of this press release, and Genetron Health does not undertake any obligation to update any forward-looking statement, except as required under applicable law.